Haller Michael J, Bell Kirstine J, Besser Rachel E J, Casteels Kristina, Couper Jenny J, Craig Maria E, Elding Larsson Helena, Jacobsen Laura, Lange Karin, Oron Tal, Sims Emily K, Speake Cate, Tosur Mustafa, Ulivi Francesca, Ziegler Anette-G, Wherrett Diane K, Marcovecchio M Loredana
Division of Endocrinology, Department of Pediatrics, University of Florida, Gainesville, Florida, USA.
Charles Perkins Centre and Faculty Medicine and Health, University of Sydney, Sydney, New South Wales, Australia.
Horm Res Paediatr. 2024;97(6):529-545. doi: 10.1159/000543035. Epub 2024 Dec 11.
The International Society for Pediatric and Adolescent Diabetes (ISPAD) guidelines represent a rich repository that serves as the only comprehensive set of clinical recommendations for children, adolescents, and young adults living with diabetes worldwide. This guideline serves as an update to the 2022 ISPAD consensus guideline on staging for type 1 diabetes (T1D). Key additions include an evidence-based summary of recommendations for screening for risk of T1D and monitoring those with early-stage T1D. In addition, a review of clinical trials designed to delay progression to Stage 3 T1D and efforts seeking to preserve beta-cell function in those with Stage 3 T1D are included. Lastly, opportunities and challenges associated with the recent US Food and Drug Administration (FDA) approval of teplizumab as an immunotherapy to delay progression are discussed. The International Society for Pediatric and Adolescent Diabetes (ISPAD) guidelines represent a rich repository that serves as the only comprehensive set of clinical recommendations for children, adolescents, and young adults living with diabetes worldwide. This guideline serves as an update to the 2022 ISPAD consensus guideline on staging for type 1 diabetes (T1D). Key additions include an evidence-based summary of recommendations for screening for risk of T1D and monitoring those with early-stage T1D. In addition, a review of clinical trials designed to delay progression to Stage 3 T1D and efforts seeking to preserve beta-cell function in those with Stage 3 T1D are included. Lastly, opportunities and challenges associated with the recent US Food and Drug Administration (FDA) approval of teplizumab as an immunotherapy to delay progression are discussed.
国际儿童和青少年糖尿病协会（ISPAD）指南是一个丰富的知识库，是全球范围内为患有糖尿病的儿童、青少年和青年提供的唯一一套全面临床建议。本指南是对2022年ISPAD关于1型糖尿病（T1D）分期的共识指南的更新。主要新增内容包括基于证据的T1D风险筛查建议摘要以及对早期T1D患者的监测。此外，还纳入了旨在延缓进展至3期T1D的临床试验综述以及在3期T1D患者中保留β细胞功能的相关努力。最后，讨论了与美国食品药品监督管理局（FDA）最近批准替普珠单抗作为延缓疾病进展的免疫疗法相关的机遇和挑战。国际儿童和青少年糖尿病协会（ISPAD）指南是一个丰富的知识库，是全球范围内为患有糖尿病的儿童、青少年和青年提供的唯一一套全面临床建议。本指南是对2022年ISPAD关于1型糖尿病（T1D）分期的共识指南的更新。主要新增内容包括基于证据的T1D风险筛查建议摘要以及对早期T1D患者的监测。此外，还纳入了旨在延缓进展至3期T1D的临床试验综述以及在3期T1D患者中保留β细胞功能的相关努力。最后，讨论了与美国食品药品监督管理局（FDA）最近批准替普珠单抗作为延缓疾病进展的免疫疗法相关的机遇和挑战。
